Press releases

Results to include nine-month data on TAXUS® Liberte™

Lawsuit alleges that the Conor CoStar™ Paclitaxel-Eluting Coronary Stent System infringes a balloon catheter patent owned by Boston Scientific

Court finds Sahajanand's Infinnium paclitaxel-eluting stent infringed two claims of an Angiotech patent

Endoscopic vessel harvesting speeds recovery and reduces pain and scarring; new products offer clinicians more choices to improve patient outcomes

A live webcast and replay of the May 4 conference session will be available

A live webcast and replay of the May 2 conference session will be available

Includes recommendations for the surveillance, analysis and performance reporting of pacemakers and implantable cardioverter defibrillators (ICDs)

Both were members of the board of directors of Guidant Corporation, which was acquired by the Company last week

Company elected to adjust the interest rates due to the closing of the Company's acquisition of Guidant Corporation

Creates a global leader in cardiovascular devices and one of the largest medical technology companies in the world

Transaction scheduled to close tomorrow

"We are very pleased that we achieved record company sales for the quarter," said Jim Tobin, President and Chief Executive Officer

New study seeks to define potential of Precision™ system to treat large population of U.S. migraine sufferers who don't respond adequately to current therapies

Company must also receive antitrust approval from the U.S. Federal Trade Commission (FTC) before it can close the Guidant transaction

A live webcast and replay of the April 18 conference call will be available

Agreement subject to approval by FTC Commissioners

Company's newest addition to its broad portfolio of vascular access products

At separate special meetings today, shareholders of each company have voted overwhelmingly to approve

Features a number of elements designed to enhance steering, handling and tracking during peripheral and coronary procedures

Diabetics and other complex patients see strong results with TAXUS stents

Company plans to appeal the judgment of the Delaware U.S. District Court

Details currently confidential; will become public when the European Commission announces its decision

ISS report notes the "compelling strategic rationale" for the combination of companies

Results of the study were published in today's edition of JAMA

Six-month results are consistent with ARRIVE I data

Complex insulin-treated diabetic population shows numerical trend toward improved MACE outcomes with TAXUS versus Cypher

TAXUS trials continue to deliver positive outcomes in complex cases

Team will lead CRM Group following acquisition of Guidant

Completes Company's application for FDA approval

Results highlight efficacy of TAXUS in most complex lesions and highest risk patients

A live webcast and replay of the March 9 conference session will be available

Shareholders of both companies to vote on March 31, 2006

A live webcast and replay of the March 7 conference session will be available

(February 15, 2006) -- Boston Scientific Corporation (NYSE: BSX) announced today that it has received reimbursement approval from the French government for its TAXUS

"We reviewed with the FDA a path to resolve the issues they have identified, and we committed to working closely with them to ensure they are resolved," said Tobin

A live webcast and replay of the February 8 conference session will be available

A live webcast and replay of the February 7 conference call will be available

Merger agreement to combine the two companies, creating one of the largest medical technology companies in the world

Study was presented at the Association for Vascular Access (AVA) Annual Conference in Savannah, GA

(January 5, 2006) -- Boston Scientific Corporation (NYSE: BSX) announced today that President and Chief Executive Officer Jim Tobin has agreed to a request from the Board of Directors to extend...

New device pass-through code is only intended for use in the hospital outpatient setting under Medicare

Boston Scientific Corporation (NYSE: BSX) today announced financial results for the year and fourth quarter ended December 31, 2005.

(December 21, 2005) -- Boston Scientific Corporation (NYSE: BSX) today announced it has made a $250,000 gift to Doctors Without Borders, an international medical humanitarian organization, in...

(December 14, 2005) -- Boston Scientific Corporation (NYSE: BSX) today announced a $500,000 contribution to the University of Minnesota Foundation to fund the creation of a Boston Scientific...

(December 6, 2005) -- Boston Scientific Corporation (NYSE: BSX) today announced that two of its senior executives are scheduled to participate in the first annual Massachusetts Conference for...

(November 23, 2005) -- Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in The Fifth Annual Merrill Lynch Med Tech Fundamentals Conference, which is being held on Thursday,...

(November 17, 2005) -- Boston Scientific Corporation (NYSE: BSX) announced today the completion of a public offering of $750 million aggregate principal amount of its senior notes under the Company

(November 10, 2005) -- Boston Scientific Corporation (NYSE: BSX) today announced that it has received approval from the U.S. Food and Drug Administration (FDA) to begin a prospective, randomized,...

and Vancouver, B.C. (November 8, 2005) -- Boston Scientific Corporation (NYSE: BSX) and Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI; TSX: ANP) announced today that they have jointly received the...

(October 31, 2005) -- Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the CIBC World Markets Sixteenth Annual Healthcare Conference, which is being held November 7-9 in...

(October 24, 2005) -- Boston Scientific Corporation (NYSE: BSX) announced today that it has acquired a portfolio of proprietary endoscopic stent technologies from Willy Rüsch GmbH (Rüsch), a...

and Washington, D.C. (October 20, 2005) -- Boston Scientific Corporation (NYSE: BSX) today announced 30-day safety data from the transitional phase of its OLYMPIA registry. The OLYMPIA registry is...

and Washington, D.C. (October 20, 2005) -- Boston Scientific Corporation (NYSE: BSX) today announced nine-month sub-population data from its TAXUS V clinical trial that further supports the...

and Washington, D.C. (October 19, 2005) -- Boston Scientific Corporation (NYSE: BSX) was recognized by physicians as a leader in the pursuit of evidence-based medicine through increased use of...

and Washington, D.C. (October 18, 2005) -- Boston Scientific Corporation (NYSE: BSX) today announced follow-up data supporting excellent long-term safety and efficacy from four of its TAXUS...

(October, 17, 2005) -- Boston Scientific Corporation (NYSE: BSX) today presented data from its BEACH clinical trial, which was designed to evaluate the benefits of carotid artery stenting (CAS) in...

, and Washington, D.C. (October 17, 2005) -- Boston Scientific Corporation (NYSE: BSX) today announced the combined results from the BLAZE and BLAZE II registries showing that its...

(October 14, 2005) -- Boston Scientific Corporation (NYSE: BSX) today announced financial results for its third quarter ended September 30, 2005 and provided revised revenue and earnings-per-share...

(October 13, 2005) -- Boston Scientific Corporation (NYSE: BSX) today introduced a new program that will offer participating medical centers in the United States a TAXUS® Express2™ stent system...

(October 13, 2005) -- Boston Scientific Corporation (NYSE: BSX) announced today that a Dutch appeals court yesterday overturned a lower court ruling and reinstated an injunction against the...

(October 10, 2005) -- Boston Scientific Corporation (NYSE: BSX) today announced the schedule of the Company

(October 7, 2005) -- Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results for the third quarter ended September 30, 2005 on Friday, October 14,...

(October 4, 2005)

(October 3, 2005) -- Boston Scientific Corporation (NYSE: BSX) announced today the grand opening of its new Maple Grove, Minnesota Research and Development facility, which includes several...

(September 19, 2005) -- Boston Scientific Corporation (NYSE: BSX) announced today the grand opening of its new Marlborough, Massachusetts office complex, which serves as the new headquarters for...

(September 16, 2005) -- Boston Scientific Corporation (NYSE: BSX) announced today that it has received clearance from the U.S. Food and Drug Administration (FDA) to market its Flextome™ Cutting...

(September 14, 2005) -- Boston Scientific Corporation (NYSE: BSX) today announced that its Wayne, New Jersey manufacturing facility has been named one of the 10 best plants in North America by...

(September 13, 2005) -- Boston Scientific Corporation (NYSE: BSX) announced today that it has received CE Mark for the Precision™ Spinal Cord Stimulation (SCS) system, Europe

(September 13, 2005) -- Boston Scientific Corporation (NYSE: BSX) today welcomed an article in the Journal of the American Medical Association (JAMA) on the TAXUS V clinical trial that found the TAXUS

(September 8, 2005) -- Boston Scientific Corporation (NYSE: BSX) announced today that it has received CE Mark for its TAXUS® Liberté™ paclitaxel-eluting stent system, the world

(September 8, 2005) -- Boston Scientific Corporation (NYSE: BSX) today announced that three of its drug-eluting stent clinical trials have been recognized as meeting the treatment guidelines of...

(September 7, 2005) -- Boston Scientific Corporation (NYSE: BSX) today commented on its third quarter performance. Speaking at the 2005 Thomas Weisel Partners Healthcare Conference in Boston,...

(September 6, 2005) -- Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the Bear Stearns 18th Annual Healthcare Conference, which is being held September 12 and 13 in New...

(September 1, 2005)

(September 1, 2005) -- Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the 2005 Thomas Weisel Partners Healthcare Conference, which is being held September 7 - 9 in...

(August 16, 2005)

(August 9, 2005) -- Boston Scientific Corporation (NYSE: BSX) today announced that the U.S. Food and Drug Administration (FDA) has granted a Humanitarian Device Exemption (HDE) approval for the...

(August 2, 2005) -- Boston Scientific Corporation (NYSE: BSX) today announced the initial activation of bilateral cochlear implants for 14-month-old identical-twin girls at the California Ear...

(July 28, 2005) -- Boston Scientific Corporation (NYSE: BSX) today announced that it has received the 2005 Best Practices in Logistics Management Gold Award from Logistics Management magazine, a...

(July 19, 2005) -- Boston Scientific Corporation (NYSE: BSX) today announced financial results for its second quarter ended June 30, 2005. Highlights: Net sales of $1.6 billion, an increase of 11...

(July 11, 2005) -- Boston Scientific Corporation (NYSE: BSX) today announced that physicians have implanted the 1,000th Precision™ Spinal Cord Stimulation System for the treatment of chronic...

(July 8, 2005) -- Boston Scientific Corporation (NYSE: BSX) today announced the U.S. launch of its Matrix2™ 360o Detachable Coils, which have been cleared by the U.S. Food and Drug...

(July 7, 2005) -- Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results for the second quarter ended June 30, 2005 on Tuesday, July 19, at 11:00...

(July 1, 2005) -- Boston Scientific Corporation (NYSE: BSX) announced today that a U.S. District Court jury in Delaware found that Johnson & Johnson's (NYSE: JNJ) CYPHER® drug-eluting stent...

(June 27, 2005) -- Boston Scientific Corporation (NYSE: BSX) today announced that it is voluntarily recalling worldwide all Hemashield® VANTAGE™ Vascular Grafts, which are used in peripheral...

(June 24, 2005) -- Boston Scientific Corporation (NYSE: BSX) today announced that it has entered into a civil settlement agreement with the U.S. Department of Justice regarding the Department's...

(June 21, 2005) -- Boston Scientific Corporation (NYSE: BSX) announced today that a jury in a patent infringement case in U.S. District Court in Delaware brought by Johnson & Johnson (NYSE: JNJ)...

(June 20, 2005) -- Boston Scientific Corporation (NYSE: BSX) today announced that it has completed enrollment in the transitional phase of the world's largest drug-eluting stent registry. The...

(June 14, 2005) -- Boston Scientific Corporation (NYSE: BSX) today announced that it has completed the final phase of the acquisition of Rubicon Medical Corporation (OTC BB: RMDC). Boston...

(June 9, 2005) -- Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in Goldman Sachs' 25th Annual Healthcare Conference, which is being held June 13 -16 in Dana Point, CA....

(June 9, 2005) -- Boston Scientific Corporation (NYSE: BSX) today announced that a Dutch court has ruled that Cordis Europa N.V. ("Cordis"), a subsidiary of Johnson & Johnson (NYSE: JNJ),...

(June 2, 2005) -- Boston Scientific Corporation (NYSE: BSX) today announced the completion of the cash tender offer for any and all outstanding shares of common stock of Rubicon Medical...

(June 1, 2005) -- Boston Scientific Corporation (NYSE: BSX) today announced that Lucia Luce Quinn has been appointed Executive Vice President of Human Resources. She will be responsible for...

and Paris, France (May 26, 2005) -- Boston Scientific Corporation (NYSE: BSX) today announced that it has enrolled its 400th patient in the world

and Paris, France (May 25, 2005) -- Boston Scientific Corporation (NYSE: BSX) today provided updated financial estimates for 2005. The Company announced the estimates at a meeting of financial...

and Paris, France (May 25, 2005) -- Boston Scientific Corporation (NYSE: BSX) today announced nine-month sub-population data from its TAXUS V clinical trial that further supports the efficacy of...

and Paris, France (May 25, 2005) -- Boston Scientific Corporation (NYSE: BSX) today announced thirty-day safety data from its ATLAS clinical trial. ATLAS is the first trial using Boston...

and Paris, France (May 25, 2005) -- Boston Scientific Corporation (NYSE: BSX) today announced results from its ARRIVE and Milestone II registries. The results were announced during a symposia...

and Paris, France (May 24, 2005) -- Boston Scientific Corporation (NYSE: BSX) today announced two-year follow-up data from its TAXUS VI clinical trial. The data demonstrated that the safety and...